Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment

Knowing these will help you avoid making suboptimal investing decisions.

TDOC : 8.87 (-3.69%)
NVAX : 9.12 (-2.46%)
PFE : 27.76 (-1.17%)
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Let's look beyond this piece of bad news from regulators.

NVAX : 9.12 (-2.46%)
SNY : 52.95 (-0.60%)
How Bad Is This News for Novavax?

Novavax stock fell 20% in one trading session on the news.

NVAX : 9.12 (-2.46%)
MRNA : 53.54 (-2.00%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 109.41 (-0.94%)
EXEL : 34.29 (+0.50%)
NVAX : 9.12 (-2.46%)
VNDA : 4.85 (+4.08%)
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 53.54 (-2.00%)
BNTX : 108.97 (-2.25%)
JNJ : 158.24 (-1.18%)
PFE : 27.76 (-1.17%)
NVAX : 9.12 (-2.46%)
SNY : 52.95 (-0.60%)
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Regulators recently approved an updated COVID shot from Novavax.

NVAX : 9.12 (-2.46%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

SBFM : 2.89 (+1.76%)
NVAX : 9.12 (-2.46%)
RGNX : 8.76 (-0.34%)
BNTX : 108.97 (-2.25%)
ABBV : 200.47 (-1.51%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

SBFM : 2.89 (+1.76%)
NVAX : 9.12 (-2.46%)
RGNX : 8.76 (-0.34%)
BNTX : 108.97 (-2.25%)
ABBV : 200.47 (-1.51%)
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?

Don't be too quick to jump on the Wall Street bandwagon.

SNY : 52.95 (-0.60%)
PFE : 27.76 (-1.17%)
NVAX : 9.12 (-2.46%)
Novavax: Q2 Earnings Snapshot

Novavax: Q2 Earnings Snapshot

NVAX : 9.12 (-2.46%)

Barchart Exclusives

What the Election Results May Mean for the Corn and Soybean Markets
Taking a look at whether the trade war comes back and what it means if it does. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar